BTIG raised the firm’s price target on Glaukos (GKOS) to $116 from $104 and keeps a Buy rating on the shares. The company reported “strong” Q3 as Glaucoma revenue of $110.2M was favorable relative to the firm’s estimate, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Cautious Outlook for Glaukos Amid Regulatory Uncertainty and Valuation Concerns
- Glaukos price target raised to $122 from $120 at Wells Fargo
- Strong Buy Rating for Glaukos Driven by iDose Success and Positive Revenue Projections
- Glaukos’s Strong Growth Prospects: Buy Rating Affirmed Amid Surpassing Sales and Promising Pipeline
- Glaukos Corp. Reports Record Q3 Sales Growth